The DOI matches its Crossref record; 74 of the 74 references it cites were found in a registry or an index.
Emerging PEGylated drugs
Abstract
PEGylation is a pharmaceutical technology that involves the covalent attachment of polyethylene glycol (PEG) to a drug to improve its pharmacokinetic, pharmacodynamic, and immunological profiles, and thus, enhance its therapeutic effect. Currently, PEGylation is used to modify proteins, peptides, oligonucleotides, antibody fragments, and small organic molecules. Research groups are striving to improve the consistencies of PEGylated drugs and to PEGylate commercialized proteins and small organic molecules. Furthermore, the PEGylations of novel medications, like oligonucleotides and antibody fragments, are being pursued to improve their bioavailabilities. This active research in the PEGylation field and the continued growth of the biopharmaceutical market predicts that PEGylated drugs have a bright future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565 · cited 1×
“In addition, the vasculatures of cancer tissues have heterogeneous endothelial linings, which can cause the accumulations of supramolecular entities like polymers and liposomes [12].”
BackgroundManns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., Goodman, Z. D., Koury, K., Ling, M.-H., & Albrecht, J. K. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06102-5 · Cited by 6,029
Effect of pegylation on pharmaceuticals
Harris, J. M., & Chess, R. B. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1033 · Cited by 3,431
Hadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
PEGylation, successful approach to drug delivery
Veronese, F. M., & Pasut, G. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03575-0 · Cited by 2,339
Abuchowski, A., McCoy, J. R., Palczuk, N. C., van Es, T., & Davis, F. F. (1977) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)40292-4 · Cited by 1,274
Peptide and protein PEGylation
Veronese, F. M. (2001) · Biomaterials · doi:10.1016/s0142-9612(00)00193-9 · Cited by 1,067
The Impact of PEGylation on Biological Therapies
Veronese, F. M., & Mero, A. (2008) · BioDrugs · doi:10.2165/00063030-200822050-00004 · Cited by 1,034
Pharmacokinetic and biodistribution properties of poly(ethylene glycol)–protein conjugates
Caliceti, P. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00108-x · Cited by 947
Maeda, H., Sawa, T., & Konno, T. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00309-1 · Cited by 925
Effective drug delivery by PEGylated drug conjugates
Greenwald, R. B., Choe, Y. H., McGuire, J., & Conover, C. D. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00180-1 · Cited by 869
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00134-4 · Cited by 662
Polymer–drug conjugation, recent achievements and general strategies
Pasut, G., & Veronese, F. M. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.008 · Cited by 616
Bailon, P., Palleroni, A., Schaffer, C. A., Spence, C. L., Fung, W.-J., Porter, J. E., Ehrlich, G. K., Pan, W., Xu, Z.-X., Modi, M. W., et al. (2001) · Bioconjugate Chemistry · doi:10.1021/bc000082g · Cited by 611
Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo
Maeda, H., Seymour, L. W., & Miyamoto, Y. (1992) · Bioconjugate Chemistry · doi:10.1021/bc00017a001 · Cited by 560
PEGylated antibodies and antibody fragments for improved therapy: a review
Chapman, A. P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00026-1 · Cited by 556
Side effects of therapy of hepatitis C and their management
Fried, M. W. (2002) · Hepatology · doi:10.1002/hep.1840360730 · Cited by 556
Goldman, S. C., Holcenberg, J. S., Finklestein, J. Z., Hutchinson, R., Kreissman, S., Johnson, F. L., Tou, C., Harvey, E., Morris, E., & Cairo, M. S. (2001) · Blood · doi:10.1182/blood.v97.10.2998 · Cited by 477
Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T., & Maeda, H. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00563.x · Cited by 470
Process economics of industrial monoclonal antibody manufacture
Farid, S. S. (2007) · Journal of Chromatography B · doi:10.1016/j.jchromb.2006.07.037 · Cited by 389
Ganson, N. J., Kelly, S. J., Scarlett, E., Sundy, J. S., & Hershfield, M. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1861 · Cited by 350
Therapeutic antibody fragments with prolonged in vivo half-lives
Chapman, A. P., Antoniw, P., Spitali, M., West, S., Stephens, S., & King, D. J. (1999) · Nature Biotechnology · doi:10.1038/11717 · Cited by 350
PEGylated Proteins: Evaluation of Their Safety in the Absence of Definitive Metabolism Studies
Webster, R., Didier, E., Harris, P., Siegel, N., Stadler, J., Tilbury, L., & Smith, D. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.106.012419 · Cited by 337
Pegaspargase: a review of clinical studies
Graham, M. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00110-8 · Cited by 322
Pharmacokinetic Consequences of Pegylation
Hamidi, M., Azadi, A., & Rafiei, P. (2006) · Drug Delivery · doi:10.1080/10717540600814402 · Cited by 301
Cheng, P. N.-M., Lam, T.-L., Lam, W.-M., Tsui, S.-M., Cheng, A. W.-M., Lo, W.-H., & Leung, Y.-C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1945 · Cited by 277
Izzo, F., Marra, P., Beneduce, G., Castello, G., Vallone, P., De Rosa, V., Cremona, F., Ensor, C. M., Holtsberg, F. W., Bomalaski, J. S., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.120 · Cited by 250
Cost-effectiveness of Treatment for Chronic Hepatitis C Infection in an Evolving Patient Population
Salomon, J. A. (2003) · JAMA · doi:10.1001/jama.290.2.228 · Cited by 244
Polyethylene glycol-conjugated pharmaceutical proteins
Bailon, P., & Berthold, W. (1998) · Pharmaceutical Science & Technology Today · doi:10.1016/s1461-5347(98)00086-8 · Cited by 243
Coiffier, B., Mounier, N., Bologna, S., Fermé, C., Tilly, H., Sonet, A., Christian, B., Casasnovas, O., Jourdan, E., Belhadj, K., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.115 · Cited by 237
Sundy, J. S., Ganson, N. J., Kelly, S. J., Scarlett, E. L., Rehrig, C. D., Huang, W., & Hershfield, M. S. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22403 · Cited by 221
SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy
Maeda, H. (1991) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(91)90040-j · Cited by 213
Obstacles and pitfalls in the PEGylation of therapeutic proteins.
Gaberc‐Porekar, V., Zore, I., Podobnik, B., & Menart, V. (2008) · PubMed · Cited by 197
Novel Prodrugs of SN38 Using Multiarm Poly(ethylene glycol) Linkers
Zhao, H., Rubio, B., Sapra, P., Wu, D., Reddy, P., Sai, P., Martinez, A., Gao, Y., Lozanguiez, Y., Longley, C., et al. (2008) · Bioconjugate Chemistry · doi:10.1021/bc700333s · Cited by 188
Enzymatic procedure for site-specific pegylation of proteins
Sato, H. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00024-8 · Cited by 187
Scott, L., Lamb, J., Smith, S., & Wheatley, D. N. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1353 · Cited by 178
GlycoPEGylation of recombinant therapeutic proteins produced in Escherichia coli
DeFrees, S., Wang, Z.-G., Xing, R., Scott, A. E., Wang, J., Zopf, D., Gouty, D. L., Sjoberg, E. R., Panneerselvam, K., Brinkman-Van der Linden, E. C. M., et al. (2006) · Glycobiology · doi:10.1093/glycob/cwl004 · Cited by 174
Chan, B., Wara, D., Bastian, J., Hershfield, M. S., Bohnsack, J., Azen, C. G., Parkman, R., Weinberg, K., & Kohn, D. B. (2005) · Clinical Immunology · doi:10.1016/j.clim.2005.07.006 · Cited by 171
Holtsberg, F. W., Ensor, M., Steiner, M. R., Bomalaski, J. S., & Clark, M. A. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00042-1 · Cited by 155
Anti-cancer PEG-enzymes: 30 years old, but still a current approach
Pasut, G., Sergi, M., & Veronese, F. M. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.04.018 · Cited by 152
Pharmacokinetic and pharmacodynamic considerations in the development of therapeutic proteins
Mahmood, I., & Green, M. D. (2005) · Clinical Pharmacokinetics · doi:10.2165/00003088-200544040-00001 · Cited by 150 · cited 1×
“PEGylation also reduces drug immunogenicities, antigenicities, and toxicities, and provides additional benefits by minimizing injection volume wastage due to adsorption at injection sites and by enhancing solubilities (Figure 1) [2-4].”
BackgroundProtein, peptide and non-peptide drug PEGylation for therapeutic application
Pasut, G., Guiotto, A., & Veronese, F. (2004) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.14.6.859 · Cited by 145
Adenosine deaminase deficiency: clinical expression, molecular basis, and therapy.
Hershfield, M. S. (1998) · PubMed · Cited by 140
Releasable PEGylation of proteins with customized linkers
Filpula, D. R., & Zhao, H. (2007) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.02.001 · Cited by 140
Identification of the Major Positional Isomer of Pegylated Interferon Alpha-2b
Wang, Y.-S., Youngster, S. K., Bausch, J. N., et al. (2000) · Biochemistry · doi:10.1021/bi000617t · Cited by 130
Synthesis, Characterization, and Pharmacokinetic Studies of PEGylated Glucagon-like Peptide-1
Lee, S., Lee, S., Youn, Y. S., Na, D. H., Chae, S. Y., Byun, Y., & Lee, K. C. (2005) · Bioconjugate Chemistry · doi:10.1021/bc049735+ · Cited by 123
Self-citationPegylated arginine deiminase: a novel anticancer enzyme agent
Feun, L. G., & Savaraj, N. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.7.815 · Cited by 123
Protected thiol-polyethylene glycol: A new activated polymer for reversible protein modification
Woghiren, C., Sharma, B., & Stein, S. (1993) · Bioconjugate Chemistry · doi:10.1021/bc00023a002 · Cited by 116
Monoclonal Antibody "Gold Rush"
Maggon, K. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781368504 · Cited by 116
Development and in vivo evaluation of an oral insulin–PEG delivery system
Calceti, P., Salmaso, S., Walker, G. F., & Bernkop‐Schnürch, A. (2004) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2004.03.015 · Cited by 114
Sinhababu, A. K., & Thakker, D. R. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00109-k · Cited by 105
Grieve, R., Roberts, J., Wright, M., Sweeting, M. J., Angelis, D. D., Rosenberg, W. M., Bassendine, M. F., Main, J., & Thomas, H. C. (2005) · Gut · doi:10.1136/gut.2005.064774 · Cited by 104
Grace, M. J., Lee, S., Bradshaw, S. L., Chapman, J., Spond, J., Cox, S., DeLorenzo, M., Brassard, D., Wylie, D. C., Cannon‐Carlson, S., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412134200 · Cited by 100
Bomalaski, J. S., Holtsberg, F. W., Ensor, M., & Clark, M. A. (2002) · PubMed · Cited by 98
Pegaptanib sodium for the treatment of neovascular age-related macular degeneration: A review
Kourlas, H., & Schiller, D. S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.01.009 · Cited by 91
Booth, C., Hershfield, M. S., Notarangelo, L. D., Buckley, R. H., Hoenig, M., Mahlaoui, N., Cavazzana, M., Aiuti, A., & Gaspar, H. B. (2007) · Clinical Immunology · doi:10.1016/j.clim.2006.12.009 · Cited by 91
Economic Analysis of Prophylactic Pegfilgrastim in Adult Cancer Patients Receiving Chemotherapy
Eldar‐Lissai, A., Cosler, L. E., Culakova, E., & Lyman, G. H. (2007) · Value in Health · doi:10.1111/j.1524-4733.2007.00242.x · Cited by 87
Ton, N. C., Parker, G. J. M., Jackson, A., Mullamitha, S., Buonaccorsi, G. A., Roberts, C., Watson, Y., Davies, K. E., Cheung, S., Hope, L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1550 · Cited by 78
Youn, Y. S., Kwon, M. J., Na, D. H., Chae, S. Y., Lee, S., & Lee, K. C. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.10.008 · Cited by 74
Self-citationSullivan, S. D., Craxı̀, A., Alberti, A., Giuliani, G., Carli, C. D., Wintfeld, N., Patel, K., & Green, J. (2004) · PharmacoEconomics · doi:10.2165/00019053-200422040-00004 · Cited by 71
Drug evaluation: ADI-PEG-20--a PEGylated arginine deiminase for arginine-auxotrophic cancers.
Shen, L., & Shen, W. (2006) · PubMed · Cited by 68
Kim, T. H. (2002) · Biomaterials · doi:10.1016/s0142-9612(01)00365-9 · Cited by 68
Shen, L.-J., Lin, W.-C., Beloussow, K., & Shen, W.-C. (2003) · Cancer Letters · doi:10.1016/s030-43835(02)00693-6 · Cited by 66 · cited 1×
“In addition, the possibility of ADI-PEG-20 resistance has been suggested, because most tumor cell lines express ASS, and thus, the citrulline produced from arginine by ADI-PEG-20 is likely to be recycled back to arginine [75].”
BackgroundLee, S., Youn, Y. S., Lee, S.-H., Byun, Y., & Lee, K. C. (2006) · Diabetologia · doi:10.1007/s00125-006-0234-3 · Cited by 66
Self-citationYoun, Y. S., Chae, S. Y., Lee, S., Jeon, J. E., Shin, H. G., & Lee, K. C. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.09.013 · Cited by 65
Self-citationEdwards, C. K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00112-1 · Cited by 59
Chae, S. Y., Jin, C., Shin, H. J., Youn, Y. S., Lee, S., & Lee, K. C. (2007) · Bioconjugate Chemistry · doi:10.1021/bc700292v · Cited by 59
Self-citationCertolizumab Pegol: In Crohn??s Disease
Blick, S. K. A., & Curran, M. P. (2007) · BioDrugs · doi:10.2165/00063030-200721030-00006 · Cited by 53
Shepherd, J., Brodin, H. F. T., Cave, C. B., Waugh, N. R., Price, A., & Gabbay, J. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050063 · Cited by 46
Pegvisomant in the treatment of acromegaly
Parkinson, C. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(03)00111-x · Cited by 42
CERA: third-generation erythropoiesis-stimulating agent
Topf, J. M. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.9.5.839 · Cited by 40
Bruno, R., Sacchi, P., Scagnolari, C., Torriani, F. J., Maiocchi, L., Patruno, S. F. A., Bellomi, F., Filice, G., & Antonelli, G. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03392.x · Cited by 36
Intranasal Delivery of PEGylated Salmon Calcitonins: Hypocalcemic Effects in Rats
Lee, K. C., Myung Ok, P. A. R. K., Na, D. H., Youn, Y. S., Lee, S. D., Yoo, S. D., Lee, H. S., & DeLuca, P. P. (2003) · Calcified Tissue International · doi:10.1007/s00223-002-0034-9 · Cited by 34
Self-citationD'Antonio, M., Louveau, I., Esposito, P., Bertolino, M., & Canali, S. (2004) · Growth Hormone & IGF Research · doi:10.1016/j.ghir.2003.12.014 · Cited by 10
Cited by
Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics
Tiwari, S., Atluri, V., Kaushik, A., Yndart, A., & Nair, M. (2019) · International Journal of Nanomedicine · doi:10.2147/ijn.s200490 · Cited by 1,308
Turecek, P. L., Bossard, M. J., Schoetens, F., & Ivens, I. A. (2016) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2015.11.015 · Cited by 733
PEGylation of therapeutic proteins
Jevševar, S., Kunstelj, M., & Porekar, V. G. (2010) · Biotechnology Journal · doi:10.1002/biot.200900218 · Cited by 681
PEG — A versatile conjugating ligand for drugs and drug delivery systems
Kolate, A., Baradia, D., Patil, S., Vhora, I., Kore, G., & Misra, A. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.046 · Cited by 648
Garay, R. P., El-Gewely, R., Armstrong, J. K., Garratty, G., & Richette, P. (2012) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.2012.720969 · Cited by 587
Metadata
- Authors
- Kang, J. S., DeLuca, P. P., & Lee, K. C.
- Venue
- Expert Opinion on Emerging Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-05-20
- Volume
- 14
- Issue
- 2
- Pages
- 363-380
- ISSN
- 1472-8214 (ISSN-L)
- 1744-7623
- OpenAlex
- W2065876461
- Cited by
- 252
- References
- 74
- FWCI
- 14.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.